PETROSCRAP.COM

Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO). The issued patent, which deepens the Company’s diverse portfolio of RNA interference (RNAi …

Read more on SYS-CON Media

This entry was posted on Thursday, May 27th, 2010 at 9:35 am and is filed under Polymer News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.